90 results found.

Multiple Sclerosis, Primary Progressive, or Multiple Sclerosis, S Clinical Trial using ibudilast; Placebo

MediciNova - Recruiting 21 years to 65 years.
- A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects With Progressive Multiple Sclerosis.
ibudilast; Placebo

Multiple Sclerosis Clinical Trial using Interferon beta-1b (Betaseron, BAY86-5046)

Bayer - Recruiting 18 years or older.
- Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferonr.
Interferon beta-1b (Betaseron, BAY86-5046)

Multiple Sclerosis Clinical Trial using rHIgM22

Acorda Therapeutics - Recruiting 18 years to 70 years.
- A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS).
rHIgM22

Relapsing Remitting MS, Secondary Progressive MS, or Primary Prog Clinical Trial using Caprylic Triglyceride; Placebo

University of Miami - Recruiting 18 years to 59 years.
- A Randomized Double-Blind Placebo-Controlled Study of Caprylic Triglyceride for Cognitive Impairment in Subjects With Multiple Sclerosis..
Caprylic Triglyceride; Placebo

Multiple Sclerosis Clinical Trial

Ospedale Civico, Lugano - Recruiting 18 years to 80 years.
- MULTIDIMENSIONAL ASSESSMENT OF FATIGUE IN MULTIPLE SCLEROSIS- Observational Study - Ticino.

Multiple Sclerosis Clinical Trial using Vitamin D; Placebo; Imaging; Lumbar puncture; Blood sampling; Urine samples

Centre Hospitalier Universitaire de NÄ«mes - Recruiting 18 years to 50 years.
- Multicentric, Randomized, Double-blind Versus Placebo Study Evaluating the Efficacy of Treatment With Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of Multiple Sclerosis (MS) After a Clinically Isolated Syndrome (CIS). Comparison of Conversion Rates After 2 Years..
Vitamin D; Placebo; Imaging; Lumbar puncture; Blood sampling; Urine samples

Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Charcot-Mari Clinical Trial using Electrical impedance myography (EIM)

State University of New York - Upstate Medical University - Recruiting 35 years to 80 years.
- Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance.
Electrical impedance myography (EIM)

Multiple Sclerosis, Weakness, or Fatigue Clinical Trial using Cross-Training healthy subjects; Cross-Training multiple sclerosis; Standard-training multiple sclerosis

Università degli Studi di Sassari - Recruiting 18 years to 65 years.
- Neurophysiological, Dynamometric, Functional and Clinical Assessment of the Cross-Training Effect in Patients With Multiple Sclerosis.
Cross-Training healthy subjects; Cross-Training multiple sclerosis; Standard-training multiple sclerosis

Relapsing Remitting Multiple Sclerosis Clinical Trial using Fingolimod

Heinrich-Heine University, Duesseldorf - Recruiting 18 years to 65 years.
- The Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis.
Fingolimod

Secondary Progressive Multiple Sclerosis Clinical Trial using BAF312; Placebo

Novartis - Recruiting 18 years to 60 years.
- A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis..
BAF312; Placebo

Multiple Sclerosis Clinical Trial using Functional Magnetic Stimulation; Resistive Expiratory Muscle Training

The Cleveland Clinic - Recruiting 18 years to 70 years.
- Cleveland Clinic Research Program: Expiratory Muscle Conditioning Using Functional Magnetic Stimulation for Patients With Multiple Sclerosis.
Functional Magnetic Stimulation; Resistive Expiratory Muscle Training

Relapsing Remitting Multiple Sclerosis Clinical Trial using Fingolimod (FTY720)

Novartis - Recruiting 18 years to 50 years.
- A Multi-centre, Open-label, Non-randomised, Parallel Group Clinical Trial to Assess the Efficacy of Fingolimod in Naive Patients Versus Fingolimod in Patients Previously Treated With Interferons or Glatiramer Acetate, Based on the Presence of Relapses in Patients With Relapsing-remitting Multiple Sclerosis.
Fingolimod (FTY720)

Relapsing Remitting Multiple Sclerosis Clinical Trial using Fingoliomod; Interferon beta 1a or interferon beta 1b or Glatiramer Acetate

Novartis - Recruiting 18 years to 65 years.
- A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/Day in Patients With Relapsing Remitting Multiple Sclerosis Who Are Candidates for MS Therapy Change From Previous Disease Modifying Therapy (EPOC).
Fingoliomod; Interferon beta 1a or interferon beta 1b or Glatiramer Acetate

Relapsing Remitting Multiple Sclerosis (RRMS) Clinical Trial using longitudinal assessment

Novartis - Recruiting 18 years to 65 years.
- A 3-year Multi-center Study to Describe the Long Term Changes of Optical Coherence Tomography (OCT) Parameters in Patients Under Treatment With Gilenyar.
longitudinal assessment

Multiple Sclerosis Clinical Trial

Carmel Medical Center - Recruiting 18 years to 70 years.
- Observational Study for Assessment of the Effect of Fampyra on the Manual Function of Persons With Multiple Sclerosis.

Relapsing-remitting Multiple Sclerosis (RRMS) Clinical Trial using fingolimod; copaxone

Novartis - Recruiting 18 years to 65 years.
- A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis.
fingolimod; copaxone

Multiple Sclerosis (MS) Clinical Trial using Laquinimod 0.6 mg; Matching Placebo; Laquinimod 1.2 mg

Teva Pharmaceutical Industries - Recruiting 18 years to 55 years.
- A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod (0.6 mg/d or 1.2 mg/d) in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).
Laquinimod 0.6 mg; Matching Placebo; Laquinimod 1.2 mg

Multiple Sclerosis Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 50 years.
- Integrating Genetic and Environmental Risk Scores Into an Algorithm to Predict Multiple Sclerosis Susceptibility.

Multiple Sclerosis Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 50 years.
- Natural History of Optic Neuritis.

Multiple Sclerosis Clinical Trial using Fatigue: Take control; MS: Take Control

Department of Veterans Affairs - Recruiting 18 years or older.
- A Randomized Trial of a Formal Group Program for Fatigue in Multiple Sclerosis.
Fatigue: Take control; MS: Take Control

Multiple Sclerosis, or Multiple Sclerosis, Relapsing-Remitting Clinical Trial using DAC-HYP

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 60 years.
- Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS).
DAC-HYP

Progressive Multifocal Leukoencephalopathy, Immune Reconstitution Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older.
- Natural History Study of Progressive Multifocal Leukoencephalopathy (PML).

Multiple Sclerosis Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 70 years.
- Evaluation of Progression in Multiple Sclerosis by Magnetic Resonance Imaging (MRI).

Multiple Sclerosis, or Primary Progressive Multiple Sclerosis Clinical Trial using Idebenone

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Open Label Extension Trial of Idebenone for Primary Progressive Multiple Sclerosis.
Idebenone

Chronic Disease, Healthy, Lyme Arthritis, Lyme Disease, or Multip Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 13 years or older.
- A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Chronic Lyme Infection and Selected Control Populations.

Multiple Sclerosis Clinical Trial using Verum arm receiving Gilenyar; Active Comparator receiving Extaviar

Charite University, Berlin, Germany - Recruiting 18 years to 55 years.
- Phase II/III Study to Investigate the Effects of Fingolimod Versus Interferon Beta-1b on Visual Recovery After Optic Neuritis.
Verum arm receiving Gilenyar; Active Comparator receiving Extaviar

Multiple Sclerosis, or Optic Neuritis Clinical Trial using Mangafodipir (Teslascan)

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 70 years.
- Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple Sclerosis.
Mangafodipir (Teslascan)

Multiple Sclerosis Clinical Trial using TERIFLUNOMIDE HMR1726

Sanofi - Recruiting 18 years or older.
- A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients.
TERIFLUNOMIDE HMR1726

Multiple Sclerosis Clinical Trial using teriflunomide HMR1726; cholestyramine; charcoal

Sanofi - Recruiting 18 years to 55 years.
- Exploratory Open Label Study to Investigate the Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Relapsing Forms of Multiple Sclerosis.
teriflunomide HMR1726; cholestyramine; charcoal

Spasticity Clinical Trial using Baclofen

Sun Pharma Advanced Research Company Limited - Recruiting 18 years to 90 years.
- A CLINICAL EVALUATION OF THE SAFETY OF BACLOFEN ER CAPSULES (GRS) WHEN ADMINISTERED ONCE DAILY TO SUBJECTS WITH SPASTICITY DUE TO MULTIPLE SCLEROSIS (MS): AN OPEN LABEL, LONG TERM, SAFETY TRIAL.
Baclofen

Multiple Sclerosis Clinical Trial using Interferon beta-1b (Betaseron, BAY86-5046)

Bayer - Recruiting 12 years to 70 years.
- Study Assessing Cognitive Performance Plus Physical Activity in Patients With Relapsing-Remitting MS Under Treatment With Betaferonr.
Interferon beta-1b (Betaseron, BAY86-5046)

Multiple Sclerosis Clinical Trial using Several diagnostic procedures

Bayer - Recruiting 18 years or older.
- BENEFIT 11 a Long-term Follow-up Study of the BENEFIT (Betaferon/Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment, 304747), BENEFIT Follow-up (305207) Studies and BENEFIT Extension (311129) Study to Further Evaluate the Progress of Patients With First Demyelinating Event Suggestive of Multiple Sclerosis.
Several diagnostic procedures

Multiple Sclerosis Clinical Trial

University at Buffalo - Recruiting 18 years to 65 years.
- A Prospective, Observational, Single-blinded, Longitudinal Optical Coherence Tomography Study of Effect of Copaxone (Glatiramer Acetate) on Retinal Nerve Fiber Layer Thickness in Patients With Relapsing-remitting Multiple Sclerosis Over 24 Months.

Multiple Sclerosis Clinical Trial using Wahls Paleo Plus; Wahls Diet

University of Iowa - Recruiting 30 years to 65 years.
- Wahls Paleo Diet and Progressive Multiple Sclerosis.
Wahls Paleo Plus; Wahls Diet

Multiple Sclerosis Clinical Trial using Acthar Gel

Mount Sinai School of Medicine - Recruiting 18 years to 65 years.
- An Open-Label Prospective Proof-Of-Concept Trial to Evaluate the Response to Acthar Gel Therapy in Patients With Multiple Sclerosis (MS) Relapses Who Have Failed To Make an Adequate Recovery After Treatment With High-Dose Intravenous Methylprednisolone.
Acthar Gel

Multiple Sclerosis Clinical Trial using Hematopoietic Stem Cell Therapy; Standard treatment with a conventional drug

Northwestern University - Recruiting 18 years to 55 years.
- Hematopoietic Stem Cell Therapy for Patients With Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy: A Randomized Study.
Hematopoietic Stem Cell Therapy; Standard treatment with a conventional drug

Relapsing Multiple Sclerosis Clinical Trial using RPC1063 low dose; RPC1063 high dose; RPC1063 placebo; Interferon á-1a; IFN á-1a placebo

Receptos, Inc. - Recruiting 18 years to 55 years.
- A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients.
RPC1063 low dose; RPC1063 high dose; RPC1063 placebo; Interferon á-1a; IFN á-1a placebo

Multiple Sclerosis Clinical Trial using Upper limbs intervention; Usual treatment

Universidad de Granada - Recruiting 18 years to 65 years.
- Intervention Focused on Lower Limbs and Functionality in Patients With Multiple Sclerosis.
Upper limbs intervention; Usual treatment

Relapsing-Remitting Multiple Sclerosis, or Multiple Sclerosis Clinical Trial using dimethyl fumarate (DMF)

Biogen Idec - Recruiting 18 years or older.
- A Multicenter, Open-Label Study Evaluating the Effectiveness of Oral TecfideraT (Dimethyl Fumarate) on MS Disease Activity and Patient-Reported Outcomes in Subjects With Relapsing-Remitting Multiple Sclerosis in the Real-World Setting.
dimethyl fumarate (DMF)

Clinically Isolated Syndrome, or Multiple Sclerosis Clinical Trial using tears and cerebrospinal fluid sampling

Lille Catholic University - Recruiting 18 years or older.
- Tear Analysis by Isoelectric Focusing in Clinically Isolated Syndrome as Multiple Sclerosis Criterion Among Patients With or Without Lesions at the Magnetic Resonance Imaging (Oligoclonal Profile of Tears).
tears and cerebrospinal fluid sampling

Multiple Sclerosis Clinical Trial using FTY720

Novartis - Recruiting 18 years or older.
- A 1-week, Open-label, Multi-center Study to Explore Conduction Abnormalities During First Dose Administration of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis.
FTY720

Multiple Sclerosis Clinical Trial using Interferon beta-1b (Betaferon, BAY 86-5046)

Bayer - Recruiting 18 years or older.
- BETASLEEP - SLEEP Quality and Functional Health Status, Fatigue, Comorbidities and Therapeutic Algorithms Among BETAferonr Treated MS Patients.
Interferon beta-1b (Betaferon, BAY 86-5046)

Primary Progressive Multiple Sclerosis,, Secondary Progressive Mu Clinical Trial using Combined program; Physiotherapy in private practice

Assistance Publique - H“pitaux de Paris - Recruiting 18 years to 80 years.
- A Multi-centre Randomised Controlled Trial to Compare the Effectiveness of Two Rehabilitation Programs in Patients With Multiple Sclerosis..
Combined program; Physiotherapy in private practice

Relapse Remitting Multiple Sclerosis Clinical Trial using VAY736; Placebo

Novartis - Recruiting 18 years to 55 years.
- A Randomized, Partially Blind, Placebo-controlled, Proof-of-concept Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity as Measured by Brain MRI Scans in Patients With Relapsing-remitting Multiple Sclerosis.
VAY736; Placebo

Multiple Sclerosis, or Relapsing-Remitting Clinical Trial using Fingolimod

Novartis - Recruiting 18 years to 65 years.
- A 12 -Month, Open-label, Multi-center Pilot Study to Explore the Health Outcomes of FTY720 in RRMS Patients Who Have Previously Been Treated With Other Disease Modifying Therapies (DMT)- Fine.
Fingolimod

Multiple Sclerosis Clinical Trial using Fingolimod; Interferon beta 1b

Novartis - Recruiting 18 years to 50 years.
- A 18-month, Open-label, Rater-blinded, Randomized, Multi-center, Active-controlled, Parallel-group Pilot Study to Assess Efficacy and Safety of Fingolimod in Comparison to Interferon Beta 1b in Treating the Cognitive Symptoms Associated to Relapsing-remitting Multiple Sclerosis and to Assess Possible Relationship of These Effects to Regional Brain Atrophy.
Fingolimod; Interferon beta 1b

Multiple Sclerosis Clinical Trial using Interferon beta-1a i.m. injections; Fingolimod oral capsules; Placebo oral capsule; Placebo i.m. injection

Novartis - Recruiting 10 years to 17 years.
- Two-year, Double-blind, Randomzied, Multicenter, Active-controlled Study to Evaluate Safety and Efficacy of Oral Fingolimod Versus Interferon Beta-1a i.m. in Pediatric Patients With Multiple Sclerosis.
Interferon beta-1a i.m. injections; Fingolimod oral capsules; Placebo oral capsule; Placebo i.m. injection

Multiple Sclerosis Clinical Trial using Rapid Infusion Rituximab

Wake Forest Baptist Health - Recruiting 18 years to 80 years.
- Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases.
Rapid Infusion Rituximab

Multiple Sclerosis Clinical Trial using Fingolimod

Novartis - Recruiting N/A or older.
- The Multi-National Pregnancy Fingolimod Exposure Registry in Multiple Sclerosis (Epidemiological Study Protocol FTY720D2404).
Fingolimod

Muscle Spasticity, or Multiple Sclerosis Clinical Trial using incabotulinumtoxinA; Placebo

Multiple Sclerosis Center of Northeastern New York - Recruiting 18 years to 65 years.
- A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Incobotulinumtoxin Type A for the Functional Improvement of Lower Extremity Spasticity in Patients With Multiple Sclerosis.
incabotulinumtoxinA; Placebo

Multiple Sclerosis Clinical Trial using AIN457

Novartis - Recruiting 18 years to 55 years.
- A 1-year Open Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis..
AIN457

Central Nervous System Disease, or Multiple Sclerosis Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 75 years.
- Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the CNS.

Multiple Sclerosis Clinical Trial using Methylphenidate (Ritalin); Placebo

Oregon Health and Science University - Recruiting 20 years to 59 years.
- Methylphenidate to Improve Balance and Walking in MS.
Methylphenidate (Ritalin); Placebo

Multiple Sclerosis Clinical Trial using Interferon beta-1b (Betaseron, BAY86-5046)

Bayer - Recruiting 12 years to 16 years.
- Study Evaluating Betaferonsr Safety and Tolerability In Pediatric Patients With Multiple Sclerosis.
Interferon beta-1b (Betaseron, BAY86-5046)

Multiple Sclerosis Clinical Trial using Harvesting and Implantation of stem cells

Ageless Regenerative Institute - Recruiting 18 years to 80 years.
- An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intrathecally and Intravenously Into Patients With Multiple Sclerosis.
Harvesting and Implantation of stem cells

Relapsing Remitting Multiple Sclerosis (RRMS) Clinical Trial using Bone marrow autologous mesenchymal stem cells transplantation

Germans Trias i Pujol Hospital - Recruiting 18 years to 50 years.
- Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis.
Bone marrow autologous mesenchymal stem cells transplantation

Multiple Sclerosis Clinical Trial using Educational intervention

Oregon Health and Science University - Recruiting 18 years to 89 years.
- Pilot Study on the Effect of the Free From Falls Program on Falls in People With Multiple Sclerosis.
Educational intervention

Multiple Sclerosis Clinical Trial using Umbilical cord mesenchymal stem cells

Translational Biosciences - Recruiting 18 years to 55 years.
- Phase 1//2 Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis.
Umbilical cord mesenchymal stem cells

Autoimmune Diseases of the Nervous System, Multiple Sclerosis, Se Clinical Trial using Tcelna; Placebo

Opexa Therapeutics, Inc. - Recruiting 18 years to 60 years.
- A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis.
Tcelna; Placebo

Multiple Sclerosis Clinical Trial using Avonex

Saint Francis Care - Recruiting 18 years to 65 years.
- Assessing Tolerability of Avonex Intramuscular Injects With a 25 Gauge Needle Versus 30 Gauge Needle.
Avonex

Multiple Sclerosis Clinical Trial using MRI

University at Buffalo - Recruiting 18 years to 65 years.
- Effect of Teriflunomide (Aubagior) on Gray Matter Pathology in Multiple Sclerosis: The 12 Months, Prospective, Observational, Single-blinded, Longitudinal Study.
MRI

Relapsing-Remitting Multiple Sclerosis Clinical Trial using Interferon beta-1b (Betaseron, BAY86-5046)

Bayer - Recruiting 18 years or older.
- Betaferonr Injection Management: Non-interventional Study on Personal Digital Assistant (PDA)Supported Effects on Adherence to a Long-term Injection Therapy (BETAPATH).
Interferon beta-1b (Betaseron, BAY86-5046)

Multiple Sclerosis Clinical Trial

Simnad, Virginia, M.D. - Recruiting 21 years or older.
- A Single Center Prospective, Open Label, Pilot Study to Assess Change in Bone Mass Density and Select Bone Turnover Biomarkers in Gilenya Treated Versus Non-Gilenya Treated Ambulatory Subjects With a Relapsing Form of Multiple Sclerosis.

Multiple Sclerosis Clinical Trial using dalfampridine; placebo

State University of New York at Buffalo - Recruiting 18 years to 60 years.
- .
dalfampridine; placebo

Multiple Sclerosis Clinical Trial

University of British Columbia - Recruiting 18 years or older.
- Canadian Pharmacogenomics Network for Drug Safety: Genetic Factors Associated With Multiple Sclerosis Treatment.

Multiple Sclerosis Clinical Trial using PET with 11C-Flumazenil

Assistance Publique - H“pitaux de Paris - Recruiting 18 years to 55 years.
- Prognosis Value of the Neuronal Damage Detected by Positrons Emission Tomography (PET) With 11C-Flumazenil in Early Multiple Sclerosis..
PET with 11C-Flumazenil

Multiple Sclerosis Clinical Trial using teriflunomide

Multiple Sclerosis Center of Northeastern New York - Recruiting 21 years to 60 years.
- Switching Relapsing Multiple Sclerosis Patients Treated With Natalizumab at Risk for Progressive Multifocal Leukoencephalopathy to Teriflunomide: Is This Safe and Effective?.
teriflunomide

Multiple Sclerosis Clinical Trial using Tysabri r (Natalizumab)

University of South Florida - Recruiting 18 years to 60 years.
- The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis.
Tysabri r (Natalizumab)

Secondary Progressive Multiple Sclerosis Clinical Trial using exercise training

Hugo W. Moser Research Institute at Kennedy Krieger, Inc. - Recruiting 18 years to 65 years.
- Evaluating the Effects of Functional Electrical Stimulation on Ambulation in Individuals With Secondary Progressive Multiple Sclerosis.
exercise training

Exercise Clinical Trial

Biogen Idec - Recruiting 18 years to 64 years.
- A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Patients With Multiple Sclerosis.

Neurogenic Lower Urinary Tract Dysfunction, Multiple Sclerosis, O Clinical Trial using fMRI; bladder filling; bladder cooling; additional post-treatment fMRI scan

University of Zurich - Recruiting 18 years to 55 years.
- The Bladder and the Brain - Investigation of the Supraspinal Neural Control of Lower Urinary Tract Function in Healthy Subjects and Patients With Neurogenic and Non-neurogenic Bladder Dysfunction Using Advanced Neuroimaging Techniques.
fMRI; bladder filling; bladder cooling; additional post-treatment fMRI scan

Multiple Sclerosis Clinical Trial using Cladribine

EMD Serono - Recruiting N/A or older.
- Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials.
Cladribine

Multiple Sclerosis Clinical Trial using Lung volume recruitment

Ottawa Hospital Research Institute - Recruiting 18 years or older.
- Lung Volume Recruitment for Lung Function and Cough Impairment in Multiple Sclerosis.
Lung volume recruitment

Relapsing Remitting Multiple Sclerosis Clinical Trial using Raltegravir

Queen Mary University of London - Recruiting 18 years to 55 years.
- A Phase II Baseline Versus Treatment Study to Determine the Efficacy of Raltegravir (Isentress) in Preventing Progression of Relapsing Remitting Multiple Sclerosis as Determined by Gadolinium-enhanced MRI.
Raltegravir

Multiple Sclerosis Clinical Trial using Trap Myelin Test

Nantes University Hospital - Recruiting 18 years to 55 years.
- Study Multicenter, Controlled, Prospective, Non-randomized Test to Analyze the Myelin-TRAP as Diagnostic Tool in Multiple Sclerosis.
Trap Myelin Test

Multiple Sclerosis, Relapsing-Remitting Clinical Trial using Hookworm larvae; Placebo

University of Nottingham - Recruiting 18 years to 65 years.
- Worms for Immune Regulation of Multiple Sclerosis (WIRMS).
Hookworm larvae; Placebo

Multiple Sclerosis Clinical Trial using IFN beta 1 a + curcumin (BCM 95); IFN beta-1a + placebo

Merck KGaA - Recruiting 18 years to 60 years.
- ProspeCtive Study to Evaluate Efficacy, Safety and tOlerability of Dietary supplemeNT of Curcumin (BCM95) in Subjects With Active Relapsing MultIple Sclerosis Treated With subcutaNeous Interferon Beta 1a 44 Mcg Three Times a Week (TIW).
IFN beta 1 a + curcumin (BCM 95); IFN beta-1a + placebo

Multiple Sclerosis Clinical Trial using Mindfulness based stress reduction (MBSR)

Stony Brook University - Recruiting 18 years to 70 years.
- Mindfulness Based Stress Reduction in MS.
Mindfulness based stress reduction (MBSR)

Autoimmune Diseases, Immune System Diseases, Demyelinating Diseas Clinical Trial using Autologous mesenchymal stem cells from adipose tissue.

Fundaci¢n P£blica Andaluza Progreso y Salud - Recruiting 18 years or older.
- Multicenter Clinical Trial Phase I / II Randomized, Placebo-controlled Study to Evaluate Safety and Feasibility of Therapy With Two Different Doses of Autologous Mesenchymal Stem Cells in Patients With Secondary Progressive Multiple Sclerosis Who do Not Respond to Treatment.
Autologous mesenchymal stem cells from adipose tissue.

Multiple Sclerosis Clinical Trial

Sheba Medical Center - Recruiting 18 years to 65 years.
- .

Multiple Sclerosis Clinical Trial using Avonex and Topamax

Multiple Sclerosis Institute - Recruiting 18 years to 55 years.
- A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis..
Avonex and Topamax

Multiple Sclerosis Clinical Trial using estroprogestins; interferon-beta 1a

S. Andrea Hospital - Recruiting 18 years to 40 years.
- Safety and Tolerability of Oral Two-Doses Estroprogestins Associated With Interferon-Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis.
estroprogestins; interferon-beta 1a